144 related articles for article (PubMed ID: 8349188)
1. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
[TBL] [Abstract][Full Text] [Related]
2. Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?
Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
Leuk Lymphoma; 1993 Jan; 9(1-2):79-83. PubMed ID: 8477205
[TBL] [Abstract][Full Text] [Related]
3. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
5. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
7. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
Azzarà A; Carulli G; Galimberti S; Baratè C; Fazzi R; Cervetti G; Petrini M
Am J Hematol; 2011 Sep; 86(9):762-7. PubMed ID: 21850658
[TBL] [Abstract][Full Text] [Related]
8. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
9. Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs.
Tsabouri SE; Georgiou I; Katsaraki A; Bourantas KL
J Exp Clin Cancer Res; 2004 Sep; 23(3):417-24. PubMed ID: 15595630
[TBL] [Abstract][Full Text] [Related]
10. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
Depaoli L; Levis A; Isabella N; Ficara F; Priotto C; Lista P; Foà R; Resegotti L
Haematologica; 1993; 78(2):118-22. PubMed ID: 8349187
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
[TBL] [Abstract][Full Text] [Related]
12. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
13. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
[TBL] [Abstract][Full Text] [Related]
15. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin treatment of idiopathic myelofibrosis.
Aloe Spiriti M; Latagliata R; Avvisati G; Battistel V; Montefusco E; Spadea A; Petti MC
Haematologica; 1993; 78(6):371-3. PubMed ID: 8175031
[TBL] [Abstract][Full Text] [Related]
17. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
18. r-huEPO in MDS: the day after.
Marqués da Costa R
Sangre (Barc); 1994 Aug; 39(4):298-9. PubMed ID: 7985061
[No Abstract] [Full Text] [Related]
19. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
[TBL] [Abstract][Full Text] [Related]
20. [Phase II clinical study of recombinant human erythropoietin on the anemia of myelodysplastic syndrome].
Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
Rinsho Ketsueki; 1993 Aug; 34(8):928-36. PubMed ID: 8411647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
